BIOMAT Database Logo BIOMAT Database Logo

Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis. 2021

Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068800 Etanercept A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS. Enbrel,Erelzi,Etanercept-szzs,Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,TNF Receptor Type II-IgG Fusion Protein,TNFR-Fc Fusion Protein,TNR 001,TNR-001,TNT Receptor Fusion Protein,TNTR-Fc,Fusion Protein, TNFR-Fc,Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein,TNF Receptor Type II IgG Fusion Protein,TNFR Fc Fusion Protein,TNR001
D000068879 Adalimumab A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS. Adalimumab-adbm,Adalimumab-atto,Amjevita,Cyltezo,D2E7 Antibody,Humira,Antibody, D2E7
D000079424 Tumor Necrosis Factor Inhibitors Compounds or agents that bind to and inhibit the synthesis or activity of TUMOR NECROSIS FACTOR-alpha. Such agents are used to treat inflammatory bowel diseases and other inflammatory diseases. TNF Antagonist,TNF Blocker,TNF Inhibitor,Tumor Necrosis Factor Antagonist,Tumor Necrosis Factor Blocker,Tumor Necrosis Factor Inhibitor,Tumor Necrosis Factor-a (TNF-a) Antagonist,Tumor Necrosis Factor-a (TNF-a) Blocker,Tumor Necrosis Factor-a (TNF-a) Inhibitor,TNF Antagonists,TNF Blockers,TNF Inhibitors,Tumor Necrosis Factor Antagonists,Tumor Necrosis Factor Blockers,Tumor Necrosis Factor-a (TNF-a) Antagonists,Tumor Necrosis Factor-a (TNF-a) Blockers,Tumor Necrosis Factor-a (TNF-a) Inhibitors,Antagonist, TNF,Antagonists, TNF,Blocker, TNF,Blockers, TNF,Inhibitor, TNF,Inhibitors, TNF
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D001681 Biological Assay A method of measuring the effects of a biologically active substance using an intermediate in vivo or in vitro tissue or cell model under controlled conditions. It includes virulence studies in animal fetuses in utero, mouse convulsion bioassay of insulin, quantitation of tumor-initiator systems in mouse skin, calculation of potentiating effects of a hormonal factor in an isolated strip of contracting stomach muscle, etc. Bioassay,Assay, Biological,Assays, Biological,Biologic Assay,Biologic Assays,Assay, Biologic,Assays, Biologic,Bioassays,Biological Assays
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face

Related Publications

Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Tumor necrosis factor inhibitors for rheumatoid arthritis.
August 2006, The New England journal of medicine,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Tumor necrosis factor inhibitors for rheumatoid arthritis.
January 1999, Bulletin on the rheumatic diseases,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Tumor necrosis factor inhibitors for rheumatoid arthritis.
November 2006, The New England journal of medicine,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Tumor necrosis factor inhibitors for rheumatoid arthritis.
November 2006, The New England journal of medicine,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Tumor necrosis factor inhibitors for rheumatoid arthritis.
November 2006, The New England journal of medicine,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Inhibitors of tumor necrosis factor for rheumatoid arthritis.
May 1999, The Journal of rheumatology. Supplement,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor.
January 2014, The open rheumatology journal,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis.
March 2017, Journal of leukocyte biology,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis.
September 2001, The Israel Medical Association journal : IMAJ,
Ching-Huang Ho, and Andrea A Silva, and Jon T Giles, and Joan M Bathon, and Daniel H Solomon, and Katherine P Liao, and I-Cheng Ho
Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis.
June 1999, Cleveland Clinic journal of medicine,
Copied contents to your clipboard!